Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orgaran versus Clexane pharmacokinetic crossover study in healthy volunteers
NL-OMON46006Active, not recruiting
- Sponsor
- Aspen Global Incorporated (AGI)
- Start
- Oct 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of danaparoid sodium and enoxaparin in thrombosis (4 arms), sponsored by Aspen Global Incorporated (AGI). Primary endpoints: Cmax ratio of anti-factor Xa activity and AUC ratio of anti-factor Xa activity. Started Oct 2017; status: active, not recruiting.
02
Drugs
danaparoid sodiumenoxaparin
03
Conditions
thrombosis
Beyond the preview
Go deeper on NL-OMON46006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46006.